Table 2.
Meta-analysis of the clinicopathological significance of HSP27 expression in patients with NSCLC
| Clinicopathological characteristics | N | No. samples | Heterogeneity (I-squared, p) | Model | OR with 95 % CI | P value | Conclusion | ||
|---|---|---|---|---|---|---|---|---|---|
| Total | PE | NE | |||||||
| Gender (male vs female) | 7 | 654 | 383 | 271 | 48.8 %, 0.069 | Random | 1.099 (0.629–1.920) | 0.740 | Not significant |
| Age (≥60 years vs <60 years) | 3 | 372 | 220 | 152 | 0.0 %, 0.570 | Fixed | 1.125 (0.637–1.986) | 0.685 | Not significant |
| Smoking status (yes vs no) | 3 | 372 | 220 | 152 | 0.0 %, 0.434 | Fixed | 1.246 (0.812–1.913) | 0.314 | Not significant |
| Differentiation (G3 vs G1 and G2) | 8 | 714 | 426 | 288 | 0.0 %, 0.644 | Fixed | 2.309 (1.645–3.242) | <0.001 | Significant |
| Lymphatic metastasis (yes vs no) | 8 | 714 | 426 | 288 | 50.8 %, 0.047 | Random | 1.425 (1.040–1.953) | 0.027 | Significant |
| TNM stage (III/IV vs I/II) | 5 | 541 | 321 | 220 | 54.8 %, 0.065 | Random | 2.10 (1.134–3.888) | 0.018 | Significant |
| Histological types (SCC vs AC) | 4 | 379 | 224 | 155 | 33.0 %, 0.214 | Fixed | 1.827 (1.171–2.849) | 0.008 | Significant |
| Tumor size (≥3 cm vs <3 cm) | 2 | 259 | 138 | 121 | 0.0 %, 0.858 | Fixed | 1.949 (1.112–3.416) | 0.020 | Significant |
AC adenocarcinoma, CI confidence interval, HSP27 heat shock protein 27, N reference count, NE negative expression, NSCLC non-small cell lung cancer, OR odds ratio, PE positive expression, SCC squamous cell carcinoma